X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the clinical development of TOUR006, which is an anti-IL-6 monoclonal antibody used for the treatment of Thyroid eye disease.
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The net proceeds will be used to fund continued clinical development of pipeline products of the company, including TOUR006, a long-acting anti-IL-6 antibody, being developed for thyroid eye disease.
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Details:
TOUR006 is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties. It is under phase 2 clinical thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
The combined company will focus on advancing Tourmaline’s lead program, TOUR006, a potentially best-in-class anti-IL-6 antibody, for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Talaris Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 19, 2023
Details:
The proceeds will be used for the development of Tourmaline’s lead program, TOUR006, a potentially best-in-class anti-IL-6 antibody, for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Acuta Capital Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 19, 2023
Details:
TOUR006 is a fully-human, anti-IL-6 antibody with differentiated properties including high binding affinity to IL-6 and a naturally long half-life, which is investigated for the treatment of thyroid eye disease.
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
The combined company will focus on advancing Tourmaline’s lead program, TOUR006, a potentially best-in-class anti-IL-6 antibody, for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Lead Product(s): TOUR006
Therapeutic Area: Immunology Product Name: TOUR006
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Tourmaline Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 22, 2023
Details:
FCR001 has the potential to restore self-tolerance in patients suffering from scleroderma and other severe autoimmune diseases by eradicating diseased autoreactive cells and regenerating a new and healthy supply of immune cells.
Lead Product(s): FCR001
Therapeutic Area: Immunology Product Name: FCR001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
The analysis identified a unique urinary cell mRNA signature that is consistent with immune quiescence as defined by the ratio of CTLA-4 to granzyme B mRNA, which is significantly higher in the FCR001 cohorts compared to the control cohorts.
Lead Product(s): Cryopreserved Allogeneic Stem Cell Therapy
Therapeutic Area: Immunology Product Name: FCR001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
The primary endpoint of FREEDOM-1 is the proportion of kidney transplant recipients treated with FCR001 who are free from chronic IS, without biopsy-proven acute rejection (BPAR), at month 24 post-transplant.
Lead Product(s): FCR001
Therapeutic Area: Immunology Product Name: FCR001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
